Research Papers:

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Hanna Styczen, Iris Nagelmeier, Tim Beissbarth, Manuel Nietert, Kia Homayounfar, Thilo Sprenger, Ute Boczek, Kathrin Stanek, Julia Kitz, Hendrik A. Wolff, Michael B. Ghadimi, Peter Middel, Torsten Liersch, Josef Rüschoff and Lena-Christin Conradi _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:15065-15076. https://doi.org/10.18632/oncotarget.3527

Metrics: PDF 1941 views  |   HTML 4037 views  |   ?  


Hanna Styczen1, Iris Nagelmeier2, Tim Beissbarth3, Manuel Nietert3, Kia Homayounfar1, Thilo Sprenger1, Ute Boczek1, Kathrin Stanek1, Julia Kitz4, Hendrik A. Wolff5, B. Michael Ghadimi1, Peter Middel2, Torsten Liersch1, Josef Rüschoff2, Lena-Christin Conradi1

1Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany

2Targos Molecular Pathology, Pathology Nordhessen, Kassel, Germany

3Department of Medical Statistics, University Medical Center, Göttingen, Germany

4Department of Pathology, University Medical Center, Göttingen, Germany

5Department of Radiotherapy and Radiooncology, University Medical Center, Göttingen, Germany

Correspondence to:

Lena-Christin Conradi, e-mail: [email protected]

Keywords: colorectal cancer, HER-2, HER-3, targeted therapy, liver metastases

Received: January 25, 2015     Accepted: March 09, 2015     Published: April 13, 2015


Objective: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.

Patients and Methods: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.

Results: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037).

Conclusions: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3527